FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis
This review describes the recently FDA-approved drugs (in the year 2022). Many of these products contain active moieties that FDA had not previously approved, either as a single ingredient or as part of a combination. These products frequently provide important new therapies for patients with multip...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/14/11/2538 |
| _version_ | 1797464246201614336 |
|---|---|
| author | Davide Benedetto Tiz Luana Bagnoli Ornelio Rosati Francesca Marini Claudio Santi Luca Sancineto |
| author_facet | Davide Benedetto Tiz Luana Bagnoli Ornelio Rosati Francesca Marini Claudio Santi Luca Sancineto |
| author_sort | Davide Benedetto Tiz |
| collection | DOAJ |
| description | This review describes the recently FDA-approved drugs (in the year 2022). Many of these products contain active moieties that FDA had not previously approved, either as a single ingredient or as part of a combination. These products frequently provide important new therapies for patients with multiple unmet diseases. The diverse small molecules are described according to the date of approval and their syntheses is discussed. This review comprises classical chemical scaffolds together with innovative drugs such as a deuterium-containing drug. |
| first_indexed | 2024-03-09T18:04:18Z |
| format | Article |
| id | doaj.art-c63a43a87d0949e1bcf319ba6731c014 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-09T18:04:18Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-c63a43a87d0949e1bcf319ba6731c0142023-11-24T09:37:25ZengMDPI AGPharmaceutics1999-49232022-11-011411253810.3390/pharmaceutics14112538FDA-Approved Small Molecules in 2022: Clinical Uses and Their SynthesisDavide Benedetto Tiz0Luana Bagnoli1Ornelio Rosati2Francesca Marini3Claudio Santi4Luca Sancineto5Group of Catalysis, Synthesis and Organic Green Chemistry, Department of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, 06123 Perugia, ItalyGroup of Catalysis, Synthesis and Organic Green Chemistry, Department of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, 06123 Perugia, ItalyGroup of Catalysis, Synthesis and Organic Green Chemistry, Department of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, 06123 Perugia, ItalyGroup of Catalysis, Synthesis and Organic Green Chemistry, Department of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, 06123 Perugia, ItalyGroup of Catalysis, Synthesis and Organic Green Chemistry, Department of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, 06123 Perugia, ItalyGroup of Catalysis, Synthesis and Organic Green Chemistry, Department of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, 06123 Perugia, ItalyThis review describes the recently FDA-approved drugs (in the year 2022). Many of these products contain active moieties that FDA had not previously approved, either as a single ingredient or as part of a combination. These products frequently provide important new therapies for patients with multiple unmet diseases. The diverse small molecules are described according to the date of approval and their syntheses is discussed. This review comprises classical chemical scaffolds together with innovative drugs such as a deuterium-containing drug.https://www.mdpi.com/1999-4923/14/11/2538FDAdrugssynthesisnew therapies |
| spellingShingle | Davide Benedetto Tiz Luana Bagnoli Ornelio Rosati Francesca Marini Claudio Santi Luca Sancineto FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis Pharmaceutics FDA drugs synthesis new therapies |
| title | FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis |
| title_full | FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis |
| title_fullStr | FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis |
| title_full_unstemmed | FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis |
| title_short | FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis |
| title_sort | fda approved small molecules in 2022 clinical uses and their synthesis |
| topic | FDA drugs synthesis new therapies |
| url | https://www.mdpi.com/1999-4923/14/11/2538 |
| work_keys_str_mv | AT davidebenedettotiz fdaapprovedsmallmoleculesin2022clinicalusesandtheirsynthesis AT luanabagnoli fdaapprovedsmallmoleculesin2022clinicalusesandtheirsynthesis AT orneliorosati fdaapprovedsmallmoleculesin2022clinicalusesandtheirsynthesis AT francescamarini fdaapprovedsmallmoleculesin2022clinicalusesandtheirsynthesis AT claudiosanti fdaapprovedsmallmoleculesin2022clinicalusesandtheirsynthesis AT lucasancineto fdaapprovedsmallmoleculesin2022clinicalusesandtheirsynthesis |